Peptech books record $28m profit
04 November, 2004 by Melissa TrudingerPeptech (ASX:PTD) has posted a record AUD$28.3 million net profit for the 2003-2004 financial year ending September 30, contrasting strongly with last year's $15.8 million loss.
Venter and crew set sail for Australian partnerships
03 November, 2004 by Renate KrelleRelaxed at the helm of his 95-foot yacht - the Sorcerer II -- on a brilliant Sydney morning, scientist and sailor J Craig Venter has started the Australian leg of his bid to circumnavigate the globe, sampling, sequencing and identifying microorganisms as he goes.
Life science VC up, but investment slows overall
01 November, 2004 by Renate KrelleThe life sciences sector once again received the largest slice of US venture capital investment in Q2 of 2004, according to a survey of the professional venture capital community. Investments in the sector amounted to US$1.26 billion -- 29 per cent of all venture capital invested.
Healthcare the focus of CSIRO's new IT centre
29 October, 2004 by Renate KrelleHealthcare projects like personal health monitoring and distance medical care will be core issues at CSIRO's new national ICT research centre.
Hong Kong's CK Life Sciences to invest $10m in Vic
28 October, 2004 by Melissa TrudingerHong Kong biotechnology company CK Life Sciences, part of the Cheung Kong group, is set to invest $10 million in R&D in Victoria, according to state premier Steve Bracks.
London calls BioComm, and Japan awaits
28 October, 2004 by Melissa TrudingerMelbourne-based licensing and business development group BioComm has opened an office in London to facilitate licensing and partnering activities in Europe.
NZ Roadshow: Signalling more cooperation
27 October, 2004 by Graeme O'NeillA leading New Zealand biotechnologist has urged Australian and New Zealand medical researchers to establish a trans-Tasman research consortium to explore the body's cell-signalling systems.
NZ Roadshow: Swim together or sink alone
27 October, 2004 by Graeme O'NeillThe Biosphere New Zealand Roadshow 2004 has hit the road in Melbourne, arguing the case for a strategic union of the biotechnology industries on either side of the Tasman Sea.
Optiscan wins FDA clearance for endomicrosope
27 October, 2004 by Renate KrelleOptiscan (ASX:OIL) has won earlier-than-expected clearance from the US Food and Drug Administration (FDA) for the flexible endomicroscope it is jointly developing with Pentax.
Optiscan wins CE Mark approval, waiting on FDA
18 October, 2004 by Renate KrelleOptiscan (ASX:OIL) has received European CE Mark approval for its flexible endo-microscope, jointly developed with Pentax. But the company and its Japanese marketing partner Pentax are awaiting a go-ahead from the US Food and Drug Administration before the marketing process gets underway.
'Open-source' initiative aims to save biotech
15 October, 2004 by Graeme O'NeillThis month, an international movement was quietly born -- one that aims to loosen the grip of the world's biggest life science corporations on key enabling technologies and patents for biotechnology R&D.
QIMR, Griffith to collaborate
14 October, 2004 by Melissa TrudingerThe Queensland Institute of Medical Research (QIMR) and Griffith University have entered into a collaboration.
Stronger old guard boosts Intersuisse biotech index
14 October, 2004 by Renate KrelleSeptember was a kind month for the biotechnology sector -- the Intersuisse biotechnology index indicated that the sector more than made up for its loss in August, moving ahead by 4 per cent, almost 1 per cent more than both the All Ordinaries and the Nasdaq.
BresaGen readies to relist
13 October, 2004 by Melissa TrudingerBresaGen (ASX:BGN) is expected to emerge from the shadow of voluntary administration this week, after shareholders voted to approve CBio's acquisition of a 51 per cent interest in the company at a general meeting on Monday.
Aussies need to get smarter about markets: VC
12 October, 2004 by Melissa TrudingerThe lack of use of market intelligence is a key distinction between Australian biotech companies and their counterparts in the US and Europe, Teraform Ventures' Haydn Wright told attendees at a BioMelbourne BioBreakfast this morning.
